Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Large variability in the alkaloid content of dietary supplements.
Front Pharmacol
January 2025
Department of Pharmacology and Vanderbilt Institute of Chemical Biology, Vanderbilt University School of Medicine, Nashville, TN, United States.
Introduction: Extracts from the rhizome of the traditional Chinese medicinal plant (CY) mediate a number of biologic effects that are associated with its content of isoquinoline alkaloids. CY alkaloids have shown analgesic, cardioprotective, and anti-addictive effects in animal models of disease. Since CY alkaloids are available to consumers as dietary supplements we analyzed the content of alkaloids in 14 products including open powders, capsules, and liquid formulations, capturing a majority of the products available online in the US.
View Article and Find Full Text PDFmHealth Incentivized Adherence Plus Patient Navigation (MIAPP): protocol for a pilot randomized controlled trial to improve linkage and retention on buprenorphine for hospitalized patients with methamphetamine use and opioid use disorder.
Addict Sci Clin Pract
January 2025
Department of Medicine, Division of General Internal Medicine, University of Washington/Harborview Medical Center, 325 9Th Avenue, Box 359780, Seattle, WA, 98104, USA.
Background: Initiation of buprenorphine for treatment of opioid use disorder (OUD) in acute care settings improves access and outcomes, however patients who use methamphetamine are less likely to link to ongoing treatment. We describe the intervention and design from a pilot randomized controlled trial of an intervention to increase linkage to and retention in outpatient buprenorphine services for patients with OUD and methamphetamine use who initiate buprenorphine in the hospital.
Methods: The study is a two-arm pilot randomized controlled trial (N = 40) comparing the mHealth Incentivized Adherence Plus Patient Navigation (MIAPP) intervention to treatment as usual.
From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS).
Sci Rep
January 2025
Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
The Relaxed Beliefs Under pSychedelics (REBUS) model proposes that serotonergic psychedelics decrease the precision weighting of neurobiologically-encoded beliefs. We conducted a preliminary examination of two psychological assumptions of REBUS: (a) psychedelics foster acute relaxation and post-acute revision of confidence in mental-health-relevant beliefs; which (b) facilitate positive therapeutic outcomes and are associated with the entropy of EEG signals. Healthy individuals (N = 11) were administered 1 mg and 25 mg psilocybin 4-weeks apart.
View Article and Find Full Text PDFElectronic cigarettes for smoking cessation.
Cochrane Database Syst Rev
January 2025
Department of Health Promotion and Policy, University of Massachusetts, Amherst, MA, USA.
Background: Electronic cigarettes (ECs) are handheld electronic vaping devices that produce an aerosol by heating an e-liquid. People who smoke, healthcare providers, and regulators want to know if ECs can help people quit smoking, and if they are safe to use for this purpose. This is a review update conducted as part of a living systematic review.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!